Abstract

Influenza virus infections can cause a broad range of symptoms, form mild respiratory problems to severe and fatal complications. While influenza virus poses a global health threat, the frequent antigenic change often significantly compromises the protective efficacy of seasonal vaccines, further increasing the vulnerability to viral infection. Therefore, it is in great need to employ strategies for the development of universal influenza vaccines (UIVs) which can elicit broad protection against diverse influenza viruses. Using a mouse infection model, we examined the breadth of protection of the caspase-triggered live attenuated influenza vaccine (ctLAIV), which was self-attenuated by the host caspase-dependent cleavage of internal viral proteins. A single vaccination in mice induced a broad reactive antibody response against four different influenza viruses, H1 and rH5 (HA group 1) and H3 and rH7 subtypes (HA group 2). Notably, despite the lack of detectable neutralizing antibodies, the vaccination provided heterosubtypic protection against the lethal challenge with the viruses. Sterile protection was confirmed by the complete absence of viral titers in the lungs and nasal turbinates after the challenge. Antibody-dependent cellular cytotoxicity (ADCC) activities of non-neutralizing antibodies contributed to cross-protection. The cross-protection remained robust even after in vivo depletion of T cells or NK cells, reflecting the strength and breadth of the antibody-dependent effector function. The robust mucosal secretion of sIgA reflects an additional level of cross-protection. Our data show that the host-restricted designer vaccine serves an option for developing a UIV, providing pan-influenza A protection against both group 1 and 2 influenza viruses. The present results of potency and breadth of protection from wild type and reassortant viruses addressed in the mouse model by single immunization merits further confirmation and validation, preferably in clinically relevant ferret models with wild type challenges.

Highlights

  • Influenza is a highly contagious respiratory disease that presents a considerable burden to public health and the economy worldwide

  • All experimental procedures were conducted with the approval of the Institutional Biosafety Committee of Yonsei University (Permit number: IBC-A202012-264-01), and animal experiments were performed with the approval of the Institutional Animal Care and Use Committee (IACUC) of the International Vaccine Institute (IVI) and strict follow-up management (Permit number: IACUC PN 2021-001)

  • The backbone of the caspase-triggered live attenuated influenza vaccine (ctLAIV) used in this study was A/Puerto Rico/8/34 (PR8, H1N1), in which the caspase cleavage sequence was introduced into two internal genes, NP and NS1 [25]

Read more

Summary

Introduction

Influenza is a highly contagious respiratory disease that presents a considerable burden to public health and the economy worldwide. Influenza viruses show considerable genetic diversity with various subtypes depending on the combination of surface hemagglutinin (HA) and/or neuraminidase (NA) genes [2, 3]. Influenza viruses, which possess segmented RNA genomes, demonstrate a high level of genetic variability, resulting in frequent antigenic changes through antigenic drift and shift [4, 5]. Due to the antigenic diversity and variability of influenza viruses, close monitoring and surveillance of influenza virus strains are required to produce effective influenza vaccines, which closely match the antigenicity of the circulating strains. The World Health Organization (WHO) annually updates its recommendations for the vaccine strains to target the viruses predicted to be the most frequently circulating in the coming season [6]. The development of a universal influenza vaccine (UIV) that can protect against various influenza viruses is highly desirable [10,11,12]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call